What have we learned from clinical neuroprotective trials?

Neurology

Volumn 57, Issue 5 SUPPL. 2, 2001, Pages

  Morgenstern, L B ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; MEDICAL ETHICS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; STROKE; TREATMENT INDICATION;

EID: 0035845603     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.57.suppl_2.s45     Document Type: Article

References (8)

1. Brain protection - Human data and potential new therapies
2. Early stroke treatment associated with better outcome: The NINDS rt-PA Stroke Study
3. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window
4. Tissue plasminogen activator plus a glutamate antagonist improves outcome after embolic stroke
5. The Enlimomab Acute Stroke Trial: Final results
6. Termination of acute stroke studies involving selfotel treatment
7. Measuring quality of life in a way that is meaningful to stroke patients
8. The Stroke Impact Scale version 2.0. Evaluation of reliability, validity, and sensitivity to change